Pharmacokinetics Clinical Trial
Official title:
A Randomized, Double-Blind Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Subcutaneous Administration of Lipegfilgrastim (Doses up to 100 μg/kg) in Healthy Japanese and Caucasian Subjects
NCT number | NCT02306915 |
Other study ID # | XM22-PK-10036 |
Secondary ID | |
Status | Completed |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | October 2014 |
Est. completion date | May 2015 |
Verified date | November 2021 |
Source | Teva Branded Pharmaceutical Products R&D, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cohorts of Japanese participants will be enrolled and treated prior to cohorts of Caucasian participants for the sake of matching. Every effort will be made to match Caucasian and Japanese participants on a cohort basis at enrollment. Reasonable effort will be made to maintain balance between male and female participants within the cohorts. There will be no replacement of participants following randomization.
Status | Completed |
Enrollment | 48 |
Est. completion date | May 2015 |
Est. primary completion date | March 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years to 45 Years |
Eligibility | Inclusion Criteria: - Body mass index (BMI) =18.0 and =25 kg/m2. - Body weight must be = 50 kg and = 90 kg. - Is in good general health as determined by medical history, physical examination, 12-lead electrocardiography (ECG), vital signs and clinical laboratory tests. - Subjects are able to read, write and understand English or Japanese; they must be able to understand the requirements of the study and be willing to comply with all trial requirements. - Female subjects of childbearing potential must have a negative serum ß-human chorionic gonadotropin (ß-hCG) test at screening and negative urine pregnancy test at check-in. All subjects must be either surgically sterile (for females that means documented complete hysterectomy, bilateral oophorectomyor bi-tubal ligations; partial hysterectomy is not sufficient), abstinent throughout the study or, if of reproductive capacity and not abstinent, exercising any 2 different forms of highly effective contraception methods with his/her partner during the entire study period. o Additional inclusion criteria for Japanese subjects: - Subject must be a non-naturalized Japanese citizen and hold a Japanese passport. - Subject must have/had 2 Japanese parents and 4 Japanese grandparents who are all non-naturalized Japanese citizens, as confirmed by interview. - Subject has been living outside of Japan for 10 years or fewer as confirmed by interview. o Additional inclusion criterion for Caucasian subjects: - The subject is Caucasian, and confirms by interview that his/her parents and grandparents are Caucasian and none are of Black/African descent, Middle-Eastern descent or Asian descent. - -other criteria apply, please contact the investigator for more information Exclusion Criteria: - History of hypersensitivity to pegfilgrastim, filgrastim, lenograstim, Escherichia coli derived proteins, or to any excipients (glacial acetic acid, sodium hydroxide, sorbitol, polysorbate 20). - Prior exposure to filgrastim, pegfilgrastim or lenograstim or other granulocyte colony stimulating factors (G-CSFs) in clinical development less than 6 months before randomization. - Findings of splenomegaly on sonography, defined by splenic length in excess of 12.3 cm (Andrews, 2000; Benter et al, 2011) and clinical judgment. - Existence or recent history of persistent pulmonary infiltrates or recent pneumonia, or current symptoms of upper respiratory infection. In the case of pneumonia, subject may be screened 12 weeks following cessation of antibiotic treatment. - -other criteria apply, please contact the investigator for more information |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Teva Investigational Site 34193 | London |
Lead Sponsor | Collaborator |
---|---|
Merckle GmbH |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PK: Area under the serum concentration-time curve (AUC), from time 0 to the last measurable concentration (AUC0-t) | 2 hours for visits 3, 9; 1 day for visit 10 | Days 1-8, 10, 14, 17, 21 | |
Primary | AUC from time 0 extrapolated to infinity (AUC0-8) | Days 1-8, 10, 14, 17, 21 | ||
Primary | Maximum observed serum drug concentration (Cmax) | Days 1-8, 10, 14, 17, 21 | ||
Primary | Time to maximum observed serum drug concentration (tmax) | Days 1-8, 10, 14, 17, 21 | ||
Primary | The percentage of the extrapolated area to infinity in relation to the total area under the curve (%AUCext) | Visits 3, 9, 10 | ||
Primary | Apparent serum terminal elimination rate constant (?z) | 2 hours for visits 3, 9; 1 day for visit 10 | Days 1-8, 10, 14, 17, 21 | |
Primary | Associated elimination half-life (t½) | Days 1-8, 10, 14, 17, 21 | ||
Primary | Mean residence time (MRT) | Days 1-8, 10, 14, 17, 21 | ||
Primary | Apparent total body clearance (CL/F) | Days 1-8, 10, 14, 17, 21 | ||
Primary | Apparent volume of distribution during the terminal phase (Vz/F) | Days 1-8, 10, 14, 17, 21 | ||
Primary | PD: ANC area over baseline effect curve (ANC AOBEC) | Days 1-8, 10, 14, 17, 21 | ||
Primary | Maximum measured ANC value after dosing (ANC Cmax) | Days 1-8, 10, 14, 17, 21 | ||
Primary | Time point at which ANC Cmax is observed (ANC tmax) | Days 1-8, 10, 14, 17, 21 | ||
Primary | Time (days) until ANC returns to baseline value | Days 1-8, 10, 14, 17, 21 | ||
Primary | CD34+ area over the baseline effect curve (CD34+ AOBEC) | Days 1-8, 10, 14, 17, 21 | ||
Primary | Maximum measured CD34+ value after dosing (CD34+ Cmax) | Days 1-8, 10, 14, 17, 21 | ||
Primary | Time point at which CD34+ Cmax is observed (CD34+ tmax) | Days 1-8, 10, 14, 17, 21 | ||
Secondary | Percentage of Participants with Adverse Events | 28 Days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04092725 -
Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04181008 -
Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers
|
Early Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT04406415 -
Oral Nafamostat in Healthy Volunteers
|
Phase 1 | |
Not yet recruiting |
NCT05421312 -
Periarticular Penetration of Cefazolin and Clindamycin in Second Stage Revision Arthroplasty of the Hip
|
Phase 4 | |
Completed |
NCT02534753 -
A Pharmacokinetics Study of Intravenous Ascorbic Acid
|
Phase 1 | |
Completed |
NCT01636024 -
To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594
|
Phase 1 | |
Completed |
NCT01682408 -
Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability
|
Phase 1 | |
Completed |
NCT01976078 -
Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents
|
N/A | |
Completed |
NCT01415102 -
A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372.
|
Phase 1 | |
Completed |
NCT01208155 -
Study in Healthy Males to Assess Bioavailability of 4 Different Fostamatinib Tablets
|
Phase 1 | |
Completed |
NCT01214941 -
Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol
|
Phase 4 | |
Completed |
NCT01260025 -
Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor
|
Phase 1 | |
Completed |
NCT00984009 -
A Drug-Food Interaction Study Between Colchicine and Grapefruit Juice
|
Phase 1 | |
Completed |
NCT00746499 -
Pharmacokinetic Study of Raltegravir in Healthy Premenopausal Women.
|
Phase 1 | |
Completed |
NCT01276119 -
The First Clinical Study to Test Safety, Blood Levels and Other Effects of CDP6038 in Healthy Males
|
Phase 1 | |
Completed |
NCT00856570 -
A Clinical Study to Determine the Effect of YM178 on the Pharmacokinetics of Warfarin in Healthy Subjects
|
Phase 1 | |
Completed |
NCT00730145 -
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
|
Phase 1 | |
Completed |
NCT00747721 -
Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU
|
Phase 1 | |
Completed |
NCT01055964 -
a Comparative Pharmacokinetic Study of Two Oral Formulations of Tacrolimus in Renal Allograft Recipients
|
Phase 3 |